Li Tiangang, Chiang John Y L
Dept. of Biochemistry and Molecular Pathology, Northeastern Ohio University College of Medicine, Rootstown, OH 44272, USA.
Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G74-84. doi: 10.1152/ajpgi.00258.2004. Epub 2004 Aug 26.
Bile acids, steroids, and drugs activate steroid and xenobiotic receptor pregnane X receptor (PXR; NR1I2), which induces human cytochrome P4503A4 (CYP3A4) in drug metabolism and cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis in the liver. Rifampicin, a human PXR agonist, inhibits bile acid synthesis and has been used to treat cholestatic diseases. The objective of this study is to elucidate the mechanism by which PXR inhibits CYP7A1 gene transcription. The mRNA expression levels of CYP7A1 and several nuclear receptors known to regulate the CYP7A1 gene were assayed in human primary hepatocytes by quantitative real-time PCR (Q-PCR). Rifampicin reduced CYP7A1 and small heterodimer partner (SHP; NR02B) mRNA expression suggesting that SHP was not involved in PXR inhibition of CYP7A1. Rifampicin inhibited CYP7A1 reporter activity and a PXR binding site was localized to the bile acid response element-I. Mammalian two-hybrid assays revealed that PXR interacted with hepatic nuclear factor 4 alpha (HNF4 alpha, NR2A1) and rifampicin was required. Coimmunoprecipitation assay confirmed PXR interaction with HNF4 alpha. PXR also interacted with peroxisome proliferator-activated receptor gamma coactivator (PGC-1 alpha), which interacted with HNF4 alpha and induced CYP7A1 gene transcription. Rifampicin enhanced PXR interaction with HNF4 alpha and reduced PGC-1 alpha interaction with HNF4 alpha. Chromatin immunoprecipitation assay showed that PXR, HNF4 alpha, and PGC-1 alpha bound to CYP7A1 chromatin, and rifampicin dissociated PGC-1 alpha from chromatin. These results suggest that activation of PXR by rifampicin promotes PXR interaction with HNF4 alpha and blocks PGC-1 alpha activation with HNF4 alpha and results in inhibition of CYP7A1 gene transcription. Rifampicin inhibition of bile acid synthesis may be a protective mechanism against drug and bile acid-induced cholestasis.
胆汁酸、类固醇和药物可激活类固醇和外源性物质受体孕烷X受体(PXR;NR1I2),该受体在药物代谢中诱导人细胞色素P4503A4(CYP3A4),在肝脏胆汁酸合成中诱导胆固醇7α-羟化酶(CYP7A1)。利福平是一种人PXR激动剂,可抑制胆汁酸合成,已被用于治疗胆汁淤积性疾病。本研究的目的是阐明PXR抑制CYP7A1基因转录的机制。通过定量实时PCR(Q-PCR)在人原代肝细胞中检测CYP7A1和几种已知调节CYP7A1基因的核受体的mRNA表达水平。利福平降低了CYP7A1和小异源二聚体伴侣(SHP;NR02B)的mRNA表达,表明SHP不参与PXR对CYP7A1的抑制作用。利福平抑制CYP7A1报告基因活性,且一个PXR结合位点定位于胆汁酸反应元件-I。哺乳动物双杂交试验表明PXR与肝细胞核因子4α(HNF4α,NR2A1)相互作用且需要利福平参与。免疫共沉淀试验证实了PXR与HNF4α的相互作用。PXR还与过氧化物酶体增殖物激活受体γ共激活因子(PGC-1α)相互作用,PGC-1α与HNF4α相互作用并诱导CYP7A1基因转录。利福平增强了PXR与HNF4α的相互作用,并减少了PGC-1α与HNF4α的相互作用。染色质免疫沉淀试验表明PXR、HNF4α和PGC-1α与CYP7A1染色质结合,且利福平使PGC-1α从染色质上解离。这些结果表明,利福平激活PXR可促进PXR与HNF4α的相互作用,并阻断PGC-1α与HNF4α的激活,从而导致CYP7A1基因转录受到抑制。利福平对胆汁酸合成的抑制作用可能是一种针对药物和胆汁酸诱导的胆汁淤积的保护机制。